PharmaEssentia Management
Management criteria checks 3/4
PharmaEssentia's CEO is Ko-Chung Lin, appointed in Jan 2017, has a tenure of 7.83 years. directly owns 1.73% of the company’s shares, worth $100.33M. The average tenure of the management team and the board of directors is 5.1 years and 3.3 years respectively.
Key information
Ko-Chung Lin
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 7.8yrs |
| CEO ownership | 1.7% |
| Management average tenure | 5.1yrs |
| Board average tenure | 3.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | NT$2b |
| Jun 30 2024 | n/a | n/a | NT$1b |
| Mar 31 2024 | n/a | n/a | NT$442m |
| Dec 31 2023 | n/a | n/a | -NT$624m |
| Sep 30 2023 | n/a | n/a | -NT$890m |
| Jun 30 2023 | n/a | n/a | -NT$1b |
| Mar 31 2023 | n/a | n/a | -NT$2b |
| Dec 31 2022 | n/a | n/a | -NT$1b |
| Sep 30 2022 | n/a | n/a | -NT$2b |
| Jun 30 2022 | n/a | n/a | -NT$2b |
| Mar 31 2022 | n/a | n/a | -NT$3b |
| Dec 31 2021 | NT$9m | NT$9m | -NT$3b |
| Sep 30 2021 | n/a | n/a | -NT$3b |
| Jun 30 2021 | n/a | n/a | -NT$3b |
| Mar 31 2021 | n/a | n/a | -NT$2b |
| Dec 31 2020 | NT$9m | NT$9m | -NT$2b |
| Sep 30 2020 | n/a | n/a | -NT$1b |
| Jun 30 2020 | n/a | n/a | -NT$862m |
| Mar 31 2020 | n/a | n/a | -NT$856m |
| Dec 31 2019 | NT$9m | NT$8m | -NT$843m |
Compensation vs Market: Insufficient data to establish whether Ko-Chung's total compensation is reasonable compared to companies of similar size in the Luxembourg market.
Compensation vs Earnings: Ko-Chung's compensation has been consistent with company performance over the past year.
CEO
Ko-Chung Lin
7.8yrs
Tenure
NT$9,389,000
Compensation
Mr. Ko-Chung Lin, Ph D., is the Founder and Chief Strategy Officer of PharmaEssentia Corporation and has been its Chief Executive Officer since January 01, 2017. He also serves as a Director at PharmaEssen...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & Chief Pharmaceutical Officer | 12.2yrs | NT$8.49m | 1.09% $ 63.1m | |
| Founder | 7.8yrs | NT$9.39m | 1.73% $ 100.3m | |
| President | no data | NT$8.49m | 0.61% $ 35.1m | |
| Accounting Manager & Senior Manager of Finance | 9.1yrs | no data | no data | |
| VP and Head of Business Operations & Strategy | 2.8yrs | no data | no data | |
| Chief Scientific Officer | 2.3yrs | no data | 0.010% $ 593.8k | |
| VP and Head of Corporate Communications & Advocacy | 2.8yrs | no data | no data | |
| Senior VP and Head of Sales & Marketing | 3.8yrs | no data | no data | |
| Senior VP & Head of People | 2.8yrs | no data | no data | |
| Chief Medical Officer | 7.8yrs | no data | 0.0061% $ 353.5k | |
| Head of Japan Medical Affairs | 6.3yrs | no data | no data | |
| Chief Operating Officer of Taichung Plant | 6.3yrs | no data | no data |
5.1yrs
Average Tenure
Experienced Management: 261280558's management team is seasoned and experienced (5.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & Chief Pharmaceutical Officer | 12.2yrs | NT$8.49m | 1.09% $ 63.1m | |
| Founder | 3.3yrs | NT$9.39m | 1.73% $ 100.3m | |
| President | 9.5yrs | NT$8.49m | 0.61% $ 35.1m | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | less than a year | no data | 0.13% $ 7.4m | |
| Independent Director | 10.7yrs | NT$120.00k | 0.029% $ 1.7m | |
| Independent Director | 6.4yrs | NT$120.00k | 0.00060% $ 34.8k | |
| Independent Director | less than a year | no data | 0.0012% $ 69.6k | |
| Chairperson of Japan | 3.5yrs | no data | no data | |
| Director | 3.3yrs | NT$95.00k | 0.24% $ 14.2m | |
| Director | less than a year | no data | no data | |
| Director | less than a year | no data | no data |
3.3yrs
Average Tenure
Experienced Board: 261280558's board of directors are considered experienced (3.3 years average tenure).